1. Scrip
  2. >>R&D

Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial

 
• By Emily Hayes

Potentially registrational trial of ADXS-DUAL Listeria-based vaccine with Bristol's PD-1 inhibitor Opdivo in recurrent metastatic cervical cancer will complement Advaxis's adjuvant study of earlier-generation candidate axalimogene filolisbac.

Cancer-cells-pink-color_1200x675

Advaxis Inc. plans to start a randomized study by the end of the year for its Listeria-based vaccine ADXS-DUAL with Bristol-Myers Squibb Co.'s PD-1 inhibitor Opdivo (nivolumab) in recurrent metastatic cervical cancer, in hopes that it could serve as a registrational trial, given the small patient population and high unmet need.

Advaxis and Bristol announced their plans to collaborate on a study of squamous and non-squamous cell cervical cancer on May...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

Altimmune’s Phase IIb MASH Data Send Share Price Plunging

 
• By Joseph Haas

Altimmune’s stock price did not recover on June 27, after a 57% dip the day before, despite efforts to position pemvidutide as both resolving MASH and offering weight loss.

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Veru’s Enobosarm Market Potential Enhanced By New Obesity Data

 
• By Aakash Babu

The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.

More from Scrip

What Incyte Investors Expect From New CEO Bill Meury

 
• By Andrew McConaghie

Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.

Bayer Buoyant After EU Nod For Twice-Yearly Eylea

 
• By Kevin Grogan

Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.

Executives On The Move: New CEO At Atalanta Therapeutics

Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.